Zealand Raises $1 Billion to Advance Amylin Obesity Drug and Seek Partnership
Zealand Pharma, Obesity, Amylin, Weight Loss, $1 Billion Raise, Partnership
Curie.Bio Raises $380M to Support Early-Stage Biotechs
Curie.Bio, biotech accelerator, venture capital, Series A rounds, early-stage biotechs, Alexis Borisy, Zach Weinberg
Formation Bio Secures $372M Megaround to In-License Over 10 Drugs
Formation Bio, Megaround, In-License, Drugs, Biotech, AI-Focused
Wave Life Sciences Achieves Breakthrough in Huntington’s Disease Treatment with WVE-003, Eyes Accelerated Approval
Wave Life Sciences, Huntington’s disease, WVE-003, Phase Ib/IIa study, accelerated approval, mutant huntingtin protein, allele-selective silencing, RNA medicine
Sarepta Therapeutics: Next Steps After Full FDA Approval for Duchenne Muscular Dystrophy Gene Therapy
Sarepta Therapeutics, Duchenne muscular dystrophy, gene therapy, FDA approval, Elevidys, microdystrophin, ambulatory patients, non-ambulatory patients, pipeline development, rare diseases, genetic medicine.
Pfizer, Bristol Myers Squibb, and Johnson & Johnson: Navigating the Looming Patent Cliff
Patent Cliff, Pharmaceutical Industry, Pfizer, Bristol Myers Squibb, Johnson & Johnson, Patent Expirations, Biologics, Biosimilars, Revenue Loss, Mergers and Acquisitions
J&J’s Tremfya Fails to Meet Primary Endpoint in Giant Cell Arteritis Trial
Tremfya, Johnson & Johnson, Giant Cell Arteritis, Phase II Trial, Primary Endpoint, Glucocorticoid-Free Remission
EvolutionaryScale Secures $142M for AI-Driven Drug Discovery
EvolutionaryScale, AI-driven drug discovery, $142M investment, drug development, pharmaceuticals
AbbVie’s Parkinson’s Disease Therapy Rejected by FDA Due to Third-Party Manufacturer Issues
AbbVie, Parkinson’s disease, FDA, ABBV-951, foscarbidopa, foslevodopa, third-party manufacturer, regulatory issues